日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors

具有黏液性组织学特征的肺腺癌:临床、基因组和免疫微环境特征以及基于免疫疗法和KRAS(G12C)抑制剂的治疗结果

Di Federico, A; Hong, L; Elkrief, A; Thummalapalli, R; Cooper, A J; Ricciuti, B; Digumarthy, S; Alessi, J V; Gogia, P; Pecci, F; Makarem, M; Gandhi, M M; Garbo, E; Saini, A; De Giglio, A; Favorito, V; Scalera, S; Cipriani, L; Marinelli, D; Haradon, D; Nguyen, T; Haradon, J; Voligny, E; Vaz, V; Gelsomino, F; Sperandi, F; Melotti, B; Ladanyi, M; Zhang, J; Gibbons, D L; Heymach, J V; Nishino, M; Lindsay, J; Rodig, S J; Pfaff, K; Sholl, L M; Wang, X; Johnson, B E; Jänne, P A; Rekhtman, N; Maugeri-Saccà, M; Heist, R S; Ardizzoni, A; Awad, M M; Arbour, K C; Schoenfeld, A J; Vokes, N I; Luo, J

Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

对 HER2 阴性乳腺癌的分子特征分析揭示了一个独特的患者亚群,该亚群具有 17q12 缺失和 ERBB2 杂合性缺失。

Qiu, X; Tarantino, P; Li, R; Grinshpun, A; Gupta, H; Hughes, M E; Kirkner, G; Scholl, L; Johnson, B E; Meyerson, M; Cherniack, A D; Jiang, Y; Zhou, N; Lin, N U; Long, H W; Tolaney, S M; Jeselsohn, R

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

COVID-19 大流行期间肿瘤临床试验中断:一项 COVID-19 与癌症结局研究

Bakouny, Z; Labaki, C; Bhalla, S; Schmidt, A L; Steinharter, J A; Cocco, J; Tremblay, D A; Awad, M M; Kessler, A; Haddad, R I; Evans, M; Busser, F; Wotman, M; Curran, C R; Zimmerman, B S; Bouchard, G; Jun, T; Nuzzo, P V; Qin, Q; Hirsch, L; Feld, J; Kelleher, K M; Seidman, D; Huang, H; Anderson-Keightly, H M; El Zarif, T; Alaiwi, S Abou; Champagne, C; Rosenbloom, T D; Stewart, P S; Johnson, B E; Trinh, Q; Tolaney, S M; Galsky, M D; Choueiri, T K; Doroshow, D B

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer

在针对晚期非小细胞肺癌患者的二线治疗中,EGFR 生物标志物可预测凡德他尼联合多西他赛的疗效,这是一项随机 III 期研究的结果。

Heymach, J V; Lockwood, S J; Herbst, R S; Johnson, B E; Ryan, A J

Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy

重新审视晚期非小细胞肺癌患者肿瘤体积和直径之间的关系:旨在最大限度地发挥每项指标在评估治疗反应中的效用

Nishino, M; Jackman, D M; DiPiro, P J; Hatabu, H; Jänne, P A; Johnson, B E

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

LKB1 肿瘤抑制基因的突变在白种人肺癌患者的肿瘤中经常被检测到,但在亚洲肺癌患者的肿瘤中则很少被检测到

Koivunen J P, Kim J, Lee J, Rogers A M, Park J O, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap B Y, Meyerson M, Wong K-K, Richards W G, Sugarbaker D J, Johnson B E, Jänne P A

Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration

载脂蛋白 E 等位基因依赖性发病机制:年龄相关性视网膜变性的模型

G Malek, L V Johnson, B E Mace, P Saloupis, D E Schmechel, D W Rickman, C A Toth, P M Sullivan, C Bowes Rickman

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

通过mRNA表达谱分析对人类肺癌进行分类,揭示了不同的腺癌亚型

Bhattacharjee, A; Richards, W G; Staunton, J; Li, C; Monti, S; Vasa, P; Ladd, C; Beheshti, J; Bueno, R; Gillette, M; Loda, M; Weber, G; Mark, E J; Lander, E S; Wong, W; Johnson, B E; Golub, T R; Sugarbaker, D J; Meyerson, M

Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors

限制性片段长度多态性研究表明,小细胞肺癌患者肿瘤中存在3p染色体等位基因的持续缺失。

Johnson, B E; Sakaguchi, A Y; Gazdar, A F; Minna, J D; Burch, D; Marshall, A; Naylor, S L

myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course

在源自小细胞肺癌患者的肿瘤细胞系中,myc家族癌基因扩增及其与临床状态和病程的关系

Johnson, B E; Ihde, D C; Makuch, R W; Gazdar, A F; Carney, D N; Oie, H; Russell, E; Nau, M M; Minna, J D